Description

7,8,9,10,10A,11-Hexahydro-3-Methyl-13H-Pyrido[1',2':3,4]Imidazo[2,1-B]Quinazolin-13-One is a complex heterocyclic organic compound with a fused polycyclic structure, serving as a key advanced pharmaceutical intermediate. Its precise molecular architecture makes it a critical building block for the synthesis of high-value, biologically active compounds. This product is primarily required by research institutions and pharmaceutical manufacturers engaged in the development of novel therapeutic agents, particularly within medicinal chemistry and process R&D.

Application

• Pharmaceutical Intermediate: A crucial precursor in the multi-step synthesis of potential drug candidates, especially those targeting the central nervous system or with specific receptor affinity.
• Medicinal Chemistry Research: Used as a scaffold or building block for constructing compound libraries in high-throughput screening and structure-activity relationship (SAR) studies.
• Process Development & Scale-Up: Serves as a reference standard and starting material for optimizing synthetic routes from laboratory to pilot and commercial scale production.
• Academic Research: Employed in university and institutional labs for studying heterocyclic chemistry, reaction mechanisms, and the synthesis of novel chemical entities.
• Contract Research & Manufacturing (CRO/CMO): Supplied to service organizations supporting the pharmaceutical industry in outsourced drug discovery and development projects.

Basic Information

Product Name	7,8,9,10,10A,11-Hexahydro-3-Methyl-13H-Pyrido[1',2':3,4]Imidazo[2,1-B]Quinazolin-13-One
CAS No.	33852-22-1
Molecular Formula	C₁₅H₁₅N₃O
Molecular Weight	253.30 g/mol
Synonyms	3-Methyl-7,8,9,10,10a,11-hexahydro-13H-pyrido[1',2':3,4]imidazo[2,1-b]quinazolin-13-one; Pyridoimidazoquinazolinone derivative; CAS 33852-22-1; Hexahydropyridoimidazoquinazolinone; Fused tricyclic quinazolinone; Advanced pharmaceutical intermediate (API Intermediate)
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management systems. Every batch undergoes comprehensive analytical testing, including HPLC for purity and identity confirmation via spectroscopic methods (NMR, IR, MS). A Certificate of Analysis (COA) detailing batch-specific results is provided with each shipment. We support development needs with custom purity grades, from research (95%+) to high-purity (98%+) standards, and can prepare material under cGMP guidelines for clinical trial applications upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at controlled room temperature (15-25°C). The container should be kept tightly sealed in a dry environment to minimize exposure to moisture. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 95.0% (Research Grade)
Purity (HPLC)	≥ 98.0% (High Purity Grade)
Loss on Drying	≤ 1.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.